Molina Healthcare faces a sharp 2026 earnings reset, but Medicaid rate normalization and improving Medicare duals could support a 2027 rebound. The stock looks more like a Hold than a Buy while execution risk remains high.
Molina Healthcare (MOH) is a specialized government-sponsored managed-care company facing a sharp 2026 earnings reset but carrying a credible 2027 recovery path. The core investment case rests on Medicaid rate normalization, stronger Medicare duals performance, and the removal of losses from the Marketplace and MAPD businesses. The counterweight is visible in the numbers: 2025 net income fell to $472M from $1.18B, free cash flow turned negative at $636M, and revenue growth slowed to -5.7% on the latest growth measure.
The second-quarter 2026 results provide both evidence and warning. Adjusted EPS was $1.51 on $10.2B of premium revenue, while the consolidated medical care ratio was 92.2%. Management raised full-year adjusted EPS guidance by $0.25 to at least $5.25, kept premium revenue guidance near $42B, and described 2026 as the trough year for Medicaid margins. Medicare duals exceeded expectations, but Marketplace losses forced a $1.50 reduction in segment earnings guidance.
For a moderate-risk investor with a medium-term horizon, MOH is a Hold rather than a clean Buy. The balance sheet has $4.3B of net cash, the forward P/E is 18.9x, and analyst consensus sits at $209.12. However, the 3/7 recent earnings beat rate, negative 2025 free cash flow, and high dependence on Medicaid funding make the recovery story execution-sensitive. The $205 Hold level is the report's sole fair value estimate.
Molina Healthcare (MOH), founded in 1980 and headquartered in Long Beach, California, provides managed healthcare services through Medicaid, Medicare, ACA Marketplace plans, and a small Other segment. The company employed approximately 19,000 people and served about 5.5 million members across 21 states at December 31, 2025.
The business is a risk-bearing insurer rather than a pure administrative services provider. States and federal programs pay per-member-per-month premiums, while Molina assumes responsibility for arranging and managing covered care. Earnings therefore depend on the relationship between premium rates, medical utilization, member acuity, and administrative costs.
Molina's 2025 revenue was $45.4B, up from $40.7B in 2024 and $27.8B in 2021. That scale has not translated into stable profitability recently. The 2025 medical care ratio rose to 91.7% from 89.1%, operating margin fell to 1.7%, and net margin declined to 1.0%. The company is large enough to win major contracts, but its thin margin structure leaves little room for pricing errors.
Medicaid is the economic engine. It generated $32.2B of 2025 premium revenue, or 74.7% of the segment total, and represented 4.568 million members at year-end. California, New York, Texas, and Washington each represented at least 10% of consolidated Medicaid premium revenue, creating both scale and contract concentration.
Management expects Medicaid to produce a 92.9% full-year MCR and a 1.2% pretax margin in 2026. The second-quarter MCR was 92.7%, medical cost trend remained near the 5% guidance assumption, and rate updates were tracking near 4%. Management also stated that Medicaid could contribute approximately $7.25 per share excluding Florida implementation effects, compared with approximately $5.75 per share for the full segment outlook.
Medicare generated $6.2B of 2025 premium revenue and had 262,000 members at year-end. The strategic emphasis is shifting toward dual-eligible products. Second-quarter Medicare MCR was 90.7%, and management raised full-year Medicare MCR guidance to 92.2%. Medicare duals are expected to contribute $1.25 per share in 2026, while the MAPD product is expected to lose $1.00 per share before its planned 2027 exit.
Marketplace produced $4.5B of 2025 premium revenue and had 655,000 members at year-end. Its economics deteriorated as Molina retained a more adverse member mix after pricing and footprint reductions. Second-quarter MCR was 88.9%, and full-year MCR guidance increased to 90%. Management expects a $0.75 per-share Marketplace loss in 2026 and plans to reduce 2027 exposure by approximately $1B of premium revenue.
Get AI research on any stock
Instant reports, daily intelligence, and an AI analyst in your pocket.
Medicaid is Molina's flagship product because it combines the largest member base, the largest revenue pool, and the strongest contract expertise. In 2025, the segment generated nearly three quarters of premium revenue. Its scale gives Molina experience with complex eligibility rules, state procurement, care coordination, and high-acuity populations.
The current weakness is a rate-and-trend mismatch. Management cited a 4% full-year rate assumption against 5% medical cost trend, while the 2025 filing described cost trends that outpaced rates. The second-quarter MCR of 92.7% shows that the pressure remains active, even though management reported stable high-cost categories such as behavioral health, professional visits, and inpatient care.
Florida Kids is the main near-term implementation burden. Management expects the new Florida CMS contract to reduce 2026 Medicaid earnings by $1.50 per share during implementation. That cost is designed to fade from the 2027 earnings base, making the contract a short-term drag and a medium-term operating test.
Molina's advantage is specialization rather than consumer brand power. The company focuses on government-sponsored care and describes its strategy as becoming the low-cost, effective, and reliable health plan for public-program customers. That concentration supports operating knowledge in Medicaid, dual-eligible care, and state procurement.
The company has reported a Medicaid reprocurement win rate above 90%, including the retention of a $2B Illinois managed Medicaid contract and a Wisconsin renewal during the second quarter. The 2025 filing also reported an 80% new-contract win rate worth $20B in premium and more than $10B of completed acquisitions since 2019. Those figures support a durable execution advantage, though they do not eliminate contract-cycle risk.
Molina is also investing in artificial intelligence tools for care management, payment integrity, and administrative efficiency. The 2025 filing specifically identified care management, value-based contracting, payment integrity, behavioral health, pharmacy, and long-term services and supports as operating priorities. These initiatives matter because a 1% improvement in Medicaid MCR has been valued by management at approximately $5 per share.
Molina's operating system links state contracts, provider networks, claims processing, government payments, and actuarial pricing. The company does not carry a traditional manufacturing supply chain. Its operational equivalent is the provider and claims network that must deliver care while keeping medical costs within fixed or formula-based premiums.
The adjusted G&A ratio was 6.5% in the second quarter, compared with full-year guidance of 6.4%. Management cited operating cost discipline, while days in claims payable stood at 44% and remained consistent with the prior quarter. These figures support a controlled administrative platform even as medical costs remain the larger earnings variable.
Operating cash flow was $788M in the first six months of 2026, driven partly by the timing of government payments in Medicaid and Marketplace. That recovery contrasts with negative operating cash flow of $535M for full-year 2025. The improvement is useful, but the quarterly pattern remains uneven, with $1.08B of operating cash flow in the first quarter followed by negative $294M in the second quarter.
Molina operates in a large public-program managed-care market shaped by Medicaid procurement, Medicare Advantage enrollment, dual-eligible integration, and ACA Marketplace regulation. The 2025 filing identifies a long-term premium revenue growth target of 11% to 13%, while the 2026 investor materials frame Medicaid, Medicare duals, Marketplace, and acquisitions as the principal growth avenues.
The market is attractive because states and federal programs continue to use managed-care plans to improve budget predictability and coordinate care. Molina's 2025 filing reported 5.491 million members, and the company served approximately 4.9 million members at June 30, 2026 after planned portfolio reductions. Scale remains important in contract bidding, provider negotiations, and fixed-cost absorption.
The market is also unforgiving. State contracts typically run three to five years with renewal options, while Medicare contracts can have one- to three-year terms. A lost award can remove a large premium stream quickly, and an underpriced award can preserve revenue while destroying margin. That combination explains why Molina is reducing Marketplace volume instead of chasing revenue for its own sake.
Like what you're reading?
Get full access to AI-powered research reports, market analysis, and portfolio tools.
Molina's customers are primarily state Medicaid agencies, CMS, and individuals enrolled through government-sponsored programs. Medicaid served 4.568 million members at December 31, 2025, making low-income families, children, people with disabilities, and long-term-care recipients the central end-user groups.
The customer relationship is multi-layered. States choose plans through competitive procurements, CMS sets Medicare rules and payment structures, and members select or are assigned to plans based on networks, quality, benefits, and state processes. Molina's 2025 filing states that Medicaid contracts in California, New York, Texas, and Washington each accounted for at least 10% of consolidated Medicaid revenue.
Marketplace customers have proven more difficult to underwrite. Management reported that Molina retained approximately 280,000 members after pricing and footprint reductions, with a heavier mix of high-cost drug users and members whose medical expense was not fully offset by risk adjustment. The result was a $0.75 per-share Marketplace loss outlook for 2026.
Molina identifies Centene (CNC), CVS Health (CVS), Elevance Health (ELV), UnitedHealth Group (UNH), and large nonprofit plans as Medicaid competitors. In Medicare, Molina competes with CVS, Humana (HUM), and UnitedHealth. Centene is the principal competitor cited for low-income Marketplace membership.
Molina's advantage against larger diversified insurers is focus. The company concentrates on government-sponsored programs and has built a meaningful Medicaid footprint. Its disadvantage is concentration: diversified competitors have broader commercial, pharmacy, provider, or Medicare platforms that can offset weakness in one government program.
The most relevant competitive evidence is Molina's contract record. Management reported a Medicaid reprocurement win rate above 90% and retained the $2B Illinois contract during the second quarter. That record supports Molina's ability to defend its franchise, while the loss of its Virginia contracts in 2025 shows that procurement risk remains real.
Molina's macro exposure is primarily fiscal and regulatory rather than commodity-driven. The One Big Beautiful Bill Act requires states to establish Medicaid work requirements, more frequent redeterminations, and cost sharing for certain Expansion populations from 2027 through 2029. Molina estimates a 15% to 20% enrollment reduction across 1.2 million Medicaid Expansion members by 2029.
The same policy environment can create offsetting benefits. Management expects Medicaid membership reductions to emerge gradually and stated that the associated acuity shift should be minor and protracted. If states incorporate recent medical-cost data into future rate setting, the rate reset can support margin recovery even as membership contracts.
Marketplace policy is a direct headwind. The 2025 filing identified the expiration of enhanced subsidies, tighter eligibility verification, and program-integrity initiatives as factors that can reduce enrollment and worsen risk-pool acuity. Molina's decision to reduce Marketplace exposure by approximately $1B in 2027 reflects that policy risk in capital allocation.
Medicare dual integration is the more constructive policy trend. CMS requirements are moving aligned Medicaid and Medicare organizations toward integrated dual-eligible special-needs products. Molina converted approximately $2B of MMP premium into new products and launched or retained several integrated duals contracts beginning January 1, 2026.
Molina has $4.3B of net cash, giving it a solid liquidity cushion even as negative 2025 free cash flow reached $636M.
Unlock the full analysis
Premium members get the complete breakdown — pick rationale, financial metrics, and recent earnings detail.
Get Full Access →Revenue reached $45.4B in 2025, but net income fell to $472M and the medical care ratio climbed to 91.7%, squeezing profitability.
Unlock the full analysis
Premium members get the complete breakdown — pick rationale, financial metrics, and recent earnings detail.
Get Full Access →Management lifted 2026 adjusted EPS guidance to at least $5.25 and still sees Medicaid as the trough year before a 2027 reset.
Unlock the full analysis
Premium members get the complete breakdown — pick rationale, financial metrics, and recent earnings detail.
Get Full Access →At 18.9x forward earnings versus $209.12 analyst consensus, Molina trades below the market’s near-term optimism but not at a deep discount.
Unlock the full analysis
Premium members get the complete breakdown — pick rationale, financial metrics, and recent earnings detail.
Get Full Access →The report’s fair value sits at $205, with upside tied to Medicaid rate normalization, stronger Medicare duals, and lower Marketplace losses.
Unlock the full analysis
Premium members get the complete breakdown — pick rationale, financial metrics, and recent earnings detail.
Get Full Access →Molina Healthcare (MOH) has a valuable franchise, but the franchise is operating through a difficult earnings cycle. Medicaid remains the foundation, Medicare duals are improving, and management has taken decisive action to reduce Marketplace and MAPD exposure. The balance sheet gives the company room to execute, while contract wins demonstrate meaningful operating competence.
The investment decision turns on whether the 2026 trough becomes a 2027 recovery. The $205 fair value estimate supports holding rather than chasing the stock. A stronger rating would require evidence of sustained Medicaid rate correction, reliable positive free cash flow, and earnings performance that improves on the recent 3/7 beat record.
Get AI-powered research reports, daily market intelligence, and a personal analyst in your pocket.
Get Full Access →Not ready to subscribe? ·
Cancel anytime
Molina Healthcare is a large government-sponsored managed care franchise with a strong balance sheet and a clear growth pipeline, but recent earnings have been pressured by medical cost inflation and contract churn. The report rates MOH a Buy, with upside tied to a recovery in margins and execution on Medicaid, Medicare, and Florida.
Molina Healthcare, Inc. (MOH) falls sharply after hours after an S&P MidCap 400 rebalance and renewed managed-care margin worries hit the stock. The move came without a fresh earnings report, suggesting trading flows and sector pressure drove the drop more than a new company-specific setback.
Strong quarterly results didn’t translate into broad gains, with Western Digital, American Express and Newmont all falling despite solid earnings. Kinder Morgan stood out as the week’s winner, rising after an EPS beat and a record natural gas project backlog.